Trial Profile
A PHASE 2, OPEN-LABEL STUDY TO PROVIDE REVISION OF SCARS RESULTING FROM SURGERY IN PRIOR STUDIES OF EXC 001
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2021
Price :
$35
*
At a glance
- Drugs PF 6473871 (Primary)
- Indications Scars
- Focus Adverse reactions
- Sponsors Pfizer
- 09 May 2014 New trial record